118 Higher Tumor Mutation Burden Is Associated With Improved Overall Survival and Predicts Response to Postoperative Immune Checkpoint Inhibitor Treatment After Resection of Brain Metastases

View at publisher Summarise with VIRAT
Authors: Poojan D. Shukla, Jia‐Shu Chen, Zain Peeran, Nadeem N. Al-Adli, Laura Huppert, Harish N. Vasudevan, Ramin A. Morshed
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

INTRODUCTION: Tumor mutation burden (TMB) correlates with survival in diverse primary cancers and may predict response to immune checkpoint inhibitor (ICI) therapy. However, there are limited data exploring how TMB impacts clinical outcomes after resection of brain metastases. METHODS: Single-center, retrospective cohort study of adult patients with clinical and molecular data available who underwent brain metastasis resection. Recursive partitioning analysis (RPA) identified optimal TMB cutoffs for “high” and “low.” Overall and local progression free survival (PFS) were assessed using Kaplan-Meier. Local PFS was defined as local control. Multivariate Firth’s penalized Cox proportional hazards regression analyses adjusted for GPA (graded prognostic assessment), primary cancer, EOR, preoperative and postoperative systemic therapy exposure, prior and postoperative radiation therapy. RESULTS: This cohort included 199 patients with 8.7 months median follow-up. 72 (36%) of patients were deceased at last follow-up and 26 (13%) experienced local progression. NSCLC was the most common primary tumor (n=60, 30%), followed by melanoma (n=35, 18%), and breast (n=31, 16%). Mean TMB was 15.8 mutations/Mb and varied significantly by primary cancer. RPA identified cutoffs of 35.45 and 27.15 mutations/MB as optimal survival thresholds for overall survival and local PFS, respectively. High TMB was associated with improved overall (HR: 0.36, 95% CI [0.1-096], p=0.042) and progression free survival (HR: 0.09, 95% CI [0-0.83], p=0.03). 59 (30%) patients received postoperative ICI therapy, median TMB was 25.4 mutations/Mb, and optimal cutoffs for overall and local PFS were both 18.25 mutations/Mb. High TMB again was associated with improved overall (HR: 0.05, 95% CI [0-0.31], p

Fields of Study & Subjects

Brain Metastases and Treatment Cancer Immunotherapy and Biomarkers Glioma Diagnosis and Treatment

Publication details

Journal / source
Neurosurgery
Volume
72
Issue
Supplement_1
Pages
16–16
Publication date
26 March 2026
Language
EN